Cargando…
Safety of Using Matrix Metalloproteinase Inhibitor in Experimental Glaucoma Filtration Surgery
We evaluated the safety of matrix metalloproteinase (MMP) inhibitor in experimental glaucoma filtration surgery in an animal model. Fifteen New Zealand white rabbits underwent an experimental trabeculectomy and were randomly allocated into 3 groups according to the adjuvant agent: no treatment group...
Autores principales: | Suh, Wool, Han, Kyung Eun, Han, Jae ryong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5334167/ https://www.ncbi.nlm.nih.gov/pubmed/28244295 http://dx.doi.org/10.3346/jkms.2017.32.4.666 |
Ejemplares similares
-
Matrix Metalloproteinases and Glaucoma
por: Kim, Moo Hyun, et al.
Publicado: (2022) -
Matrix Metalloproteinases and Glaucoma Treatment
por: Weinreb, Robert N., et al.
Publicado: (2020) -
A Pilot Study on Ocular Safety and Efficacy of Infliximab as an Antifibrotic Agent After Experimental Glaucoma Filtration Surgery
por: Nikita, Eleni, et al.
Publicado: (2017) -
Matrix Metalloproteinase-9 and Tissue Inhibitor of Matrix Metalloproteinase-1 in Sepsis after Major Abdominal Surgery
por: Bojic, Suzana, et al.
Publicado: (2018) -
Matrix metalloproteinases and tissue inhibitors of metalloproteinases in the aqueous humour of patients with primary angle closure glaucoma - a quantitative study
por: Nga, Angeline DC, et al.
Publicado: (2014)